Back to Search
Start Over
Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial
- Source :
- EXCLI Journal
- Publication Year :
- 2019
- Publisher :
- IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund, 2019.
-
Abstract
- The optimal pharmacological regimen for eradication of Helicobacter pylori (H. pylori) has been investigated for many years. This study aimed to evaluate the efficacy and tolerability of bismuth-based quadruple therapy (B-QT) and a modified sequential therapy (ST) regimens in eradication of H. pylori. A randomized, double-blind trial was conducted on 344 patients. Patients with H. pylori infection and without a history of previous treatment were randomized to receive 14-day B-QT (bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily) or 14-day ST (bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and metronidazole 500 mg twice a day for seven days followed by bismuth subcitrate 240 mg, pantoprazole 40 mg, amoxicillin 1000 mg, and furazolidone 100 mg twice a day for additional seven days). Drug adverse effects were assessed during the study. H. pylori eradication was determined eight weeks after the end of treatment using 14C-urea breath test. Based on per-protocol and intention-to-treat, the eradication rate was significantly higher (p<br />EXCLI Journal; 18:Doc644; ISSN 1611-2156
Details
- Language :
- English
- ISSN :
- 16112156
- Database :
- OpenAIRE
- Journal :
- EXCLI Journal
- Accession number :
- edsair.doi.dedup.....172adcb76021e0da9283d4bc2f692d1d
- Full Text :
- https://doi.org/10.17179/excli2019-1613